Cyclic Peptide Technology Enables Oral Insulin Delivery That Actually Works in Diabetic Mice | Research

The takeaway

A small intestine-permeable cyclic peptide carrier enables oral delivery of zinc-stabilized insulin hexamers in diabetic mice, achieving rapid and sustained blood sugar reduction.

Oral insulin works in mice
DNP-V peptide carrier enables intestinal insulin absorption with sustained glycemic effect

What the researchers found

DNP-V cyclic peptide carrier enables efficient oral delivery of zinc-stabilized insulin hexamers with rapid, robust, and sustained glycemic efficacy in diabetic mice.

Why it matters

If oral insulin works in humans, it would eliminate billions of daily injections worldwide and dramatically improve diabetes management adherence and quality of life.

How the study worked

Peptide engineering of DNP-V carrier; co-administration with zinc-stabilized insulin hexamers; oral dosing in diabetic mouse models; blood glucose monitoring.

What this study cannot tell us

Mouse model — human intestinal permeability differs significantly; scale-up of peptide carrier manufacturing; bioavailability and dose-response in humans unknown.

How to read the evidence

Preclinical mouse study — promising proof of concept but many oral insulin candidates have failed in human translation.

When this study was published

Published in 2026, representing the latest advance in the long quest for oral insulin delivery.

The bigger picture

This represents a breakthrough in oral protein delivery — using peptide carriers to ferry large therapeutic proteins across the intestinal barrier, potentially applicable to many injectable drugs beyond insulin.

Questions still open

What is the oral bioavailability of insulin delivered with DNP-V in larger animal models?
Could this platform deliver other injectable peptide drugs like GLP-1 agonists orally?

Common questions

Could this mean insulin pills instead of injections?

In mice, this technology enabled oral insulin that effectively lowered blood sugar. If it translates to humans, it could replace daily insulin injections with pills — but many technical challenges remain.

Why has oral insulin been so difficult to develop?

Insulin is a protein that gets destroyed by stomach acid and digestive enzymes, and even if it survives, it's too large to cross the intestinal wall. This cyclic peptide carrier solves both problems by protecting insulin and shuttling it across the intestinal barrier.

Read the original research

Small Intestine-Permeable Cyclic Peptide-Based Technology Enables Efficient Oral Delivery and Glycemic Efficacy of Zinc-Stabilized Insulin Hexamer and Its Analogs in Diabetic Mice.

Molecular pharmaceutics, 23(1), 252-264

View on PubMed ↗Publisher’s paper ↗

Citation

Chikamatsu, Shoma; Sakaguchi, Kosei; Michigami, Masataka; Araki, Kimi; Kume, Shoen; Tokuyasu, Midori; Masuda, Takeshi; Fujii, Ikuo; Ohtsuki, Sumio; Ito, Shingo. (2026). Small Intestine-Permeable Cyclic Peptide-Based Technology Enables Efficient Oral Delivery and Glycemic Efficacy of Zinc-Stabilized Insulin Hexamer and Its Analogs in Diabetic Mice.. Molecular pharmaceutics, 23(1), 252-264. https://doi.org/10.1021/acs.molpharmaceut.5c00902